November 11, 2025 — Leads & Copy — Repair Biotechnologies, Inc. presented preclinical data at the American Heart Association’s (AHA) Scientific Sessions 2025, which took place November 7-10 in New Orleans, Louisiana, supporting the ability of its drug REP-0003 to safely and rapidly reduce established atherosclerotic plaque.
Repair Biotechnologies is developing REP-0003 therapy, which is based on its proprietary Cholesterol Degrading Platform (CDP). The CDP is capable of safely breaking down the previously undruggable target of excess free cholesterol inside cells.
Excess free cholesterol is toxic to cells and contributes to the development of numerous conditions with high unmet medical need, including the accelerated growth of atherosclerotic lesions that characterizes patients with homozygous familial hypercholesterolemia (HoFH). According to the company, established therapies that reduce LDL-cholesterol in the bloodstream have little effect on intracellular free cholesterol.
Dr. Mourad Topors, Chief Scientific Officer of Repair Biotechnologies, said preclinical data demonstrates safe, rapid regression of established atherosclerotic plaque in the Lldr-/- mouse model following six weeks of treatment with REP-0003. Dr. Topors added the results and safety profile reinforce the company’s belief in the utility of selective clearance of intracellular free cholesterol as a potential treatment for HoFH. He also stated the company has been encouraged by the growing interest in this previously undruggable target following its award of Orphan Drug Designation by the U.S. Food and Drug Administration in May of this year for the treatment of HoFH.
The Repair Biotechnologies poster, “Selective Degradation of Excess Free Cholesterol in the Liver by REP-0003 Regresses Atherosclerotic Plaque in Ldlr -/- Mice: A Novel Approach for HoFH”, was presented in a moderated digital poster session on November 9 by Dr. Topors. The AHA’s Scientific Sessions is a yearly gathering in cardiovascular research and medicine, drawing experts from more than 100 nations.
Reason, CEO and Co-Founder of Repair Biotechnologies, can be reached at press@repairbiotechnologies.com or +1 315-299-2407.
Source: Repair Biotechnologies, Inc.
